Oxford, United Kingdom

Rebecca Miller


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Rebecca Miller: Innovator in Therapeutic Compounds

Introduction

Rebecca Miller is a prominent inventor based in Oxford, GB. She has made significant contributions to the field of therapeutic agents, particularly in the treatment of proliferative diseases such as cancer. With a total of 2 patents to her name, her work is paving the way for innovative treatments.

Latest Patents

Rebecca's latest patents include "Compounds and methods useful in the treatment of a PRMT5-mediated disorder." This patent focuses on compounds that inhibit protein arginine methyl-transferase (PRMT), specifically PRMT5. These compounds are intended for use as therapeutic agents in the treatment and prevention of proliferative diseases, including cancer. Another notable patent is "Tricyclic compounds for use in treatment of proliferative disorders." This invention relates to specific compounds and their pharmaceutical compositions, aimed at treating or preventing PRMT5-mediated disorders.

Career Highlights

Rebecca Miller is associated with Argonaut Therapeutics Limited, where she continues to advance her research and development efforts. Her work is characterized by a commitment to finding effective treatments for serious health conditions.

Collaborations

Rebecca collaborates with esteemed colleagues such as Andrew Morley and Nicholas La Thangue, contributing to a dynamic research environment that fosters innovation.

Conclusion

Rebecca Miller's contributions to the field of therapeutic compounds highlight her role as a leading inventor in the fight against cancer. Her innovative patents and collaborations are instrumental in developing new treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…